Home Biosimilar Antibodies Angiogenesis FGFR antibody Burosumab (Anti-FGF23) For research use only.
Not for use in humans.

Burosumab (Anti-FGF23)

Synonyms: KRN23

Burosumab (Anti-FGF23) is a neutralizing antibody, targeting human fibroblast growth factor 23 (FGF23). It can be used for the research of X-linked hypophosphatemia (XLH) and tumor-induced osteomalacia. MW: 145.5 KD.

Burosumab (Anti-FGF23)

Purity & Quality Control

≥99

Choose Selective FGFR Inhibitors

Biological Activity

Description Burosumab (Anti-FGF23) is a neutralizing antibody, targeting human fibroblast growth factor 23 (FGF23). It can be used for the research of X-linked hypophosphatemia (XLH) and tumor-induced osteomalacia. MW: 145.5 KD.

Product Details

CAS No. 1610833-03-8
Molecular Weight 145.5 kDa
Isotype Human IgG1
Source CHO
Purification AKTA
Sterility 0.2 μM filtered
Formulation 100mMPro-Ac,20mMArg-Ac，pH5.0
Storage
(From the date of receipt)		 Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.

Tech Support

If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy Burosumab (Anti-FGF23) | Burosumab (Anti-FGF23) supplier | purchase Burosumab (Anti-FGF23) | Burosumab (Anti-FGF23) cost | Burosumab (Anti-FGF23) manufacturer | order Burosumab (Anti-FGF23) | Burosumab (Anti-FGF23) distributor